TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NLS Pharmaceutics ( (NLSP) ) just unveiled an update.
On September 17, 2025, NLS Pharmaceutics Ltd. announced a change in its independent registered public accounting firm, engaging CBIZ CPAs P.C. following the resignation of Marcum LLP. This transition was prompted by CBIZ’s acquisition of Marcum’s attestation business. Despite the change, there were no disagreements or adverse opinions in the financial statements for the fiscal year ending December 31, 2024, although there were noted material weaknesses in internal controls.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a company based in Zurich, Switzerland, operating within the pharmaceutical industry. The company focuses on developing therapies for rare and complex central nervous system disorders.
Average Trading Volume: 221,780
Technical Sentiment Signal: Sell
Current Market Cap: $8.63M
See more insights into NLSP stock on TipRanks’ Stock Analysis page.